Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/388.25)
-
Patent number: 8652475Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.Type: GrantFiled: August 3, 2007Date of Patent: February 18, 2014Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporateInventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
-
Patent number: 8652471Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.Type: GrantFiled: December 20, 2012Date of Patent: February 18, 2014Assignee: Novo Nordisk A/SInventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
-
Patent number: 8618263Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.Type: GrantFiled: December 18, 2009Date of Patent: December 31, 2013Assignee: Novo Nordisk A/SInventors: Ida Hilden, Jes Thorn Clausen
-
Patent number: 8614298Abstract: Humanized anti-A? antibodies derived from a murine antibody directed to a N-terminal epitope of A? are described. The humanized antibodies have reduced or no human T cell epitopes and bind A? with an affinity similar to that of the murine antibody.Type: GrantFiled: March 21, 2011Date of Patent: December 24, 2013Assignee: Medtronic, Inc.Inventors: Lisa Lynn Shafer, Francis Joseph Carr, James Peter Gregson, Dawn Ann Bembridge, Tim Jones
-
Patent number: 8613924Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.Type: GrantFiled: August 5, 2010Date of Patent: December 24, 2013Assignee: Immunas Pharma, Inc.Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Naofumi Takamatsu, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii
-
Patent number: 8609817Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.Type: GrantFiled: July 29, 2009Date of Patent: December 17, 2013Assignee: Eli Lilly and CompanyInventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
-
Publication number: 20130331282Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.Type: ApplicationFiled: April 18, 2013Publication date: December 12, 2013Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim
-
Patent number: 8604171Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: July 27, 2012Date of Patent: December 10, 2013Assignee: Tanox, Inc.Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Publication number: 20130323751Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.Type: ApplicationFiled: January 20, 2012Publication date: December 5, 2013Applicant: University of Pittsburgh - of the Common-Wealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, JR.
-
Publication number: 20130289246Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies, including novel immunogens for use in vaccination and production of protective immune responses.Type: ApplicationFiled: September 30, 2011Publication date: October 31, 2013Applicant: VANDERBILT UNIVERSITYInventors: James E. Crowe, Jens C. Krause, David L. Blum
-
Patent number: 8568724Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.Type: GrantFiled: June 19, 2012Date of Patent: October 29, 2013Inventor: Erik Hack
-
Patent number: 8569242Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.Type: GrantFiled: December 27, 2011Date of Patent: October 29, 2013Assignee: The Regents of the University of CaliforniaInventor: Katerina Akassoglou
-
Patent number: 8557535Abstract: A method of preparing a fibrinogen rich composition is disclosed. One embodiment of the method involves contacting plasma with a hydrogel capable of increasing in mass upon contact with said plasma; maintaining said contact for a period of time sufficient for said hydrogel to absorb a substantial amount of at least the water from said plasma to produce a swollen hydrogel and a fibrinogen rich phase; and separating said fibrinogen rich phase from said swollen hydrogel; whereby said fibrinogen rich composition is produced.Type: GrantFiled: September 9, 2009Date of Patent: October 15, 2013Assignee: Incept LLCInventor: Chandrashekhar P. Pathak
-
Publication number: 20130266576Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.Type: ApplicationFiled: September 15, 2011Publication date: October 10, 2013Applicant: NOVO NORDISK A/SInventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen
-
Publication number: 20130253174Abstract: Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.Type: ApplicationFiled: April 28, 2011Publication date: September 26, 2013Applicant: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Hitoshi Chiba, Seiichi Kobayashi, Hiroyuki Furukawa
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Patent number: 8497350Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.Type: GrantFiled: June 5, 2009Date of Patent: July 30, 2013Assignee: University of Iowa Research FoundationInventor: Gregory S. Hageman
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Patent number: 8481684Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.Type: GrantFiled: August 9, 2012Date of Patent: July 9, 2013Assignee: Philogen S.p.A.Inventors: Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
-
Patent number: 8470321Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human ?-amyloid peptide as compare to low molecular weight forms of ?-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of ?-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.Type: GrantFiled: November 14, 2008Date of Patent: June 25, 2013Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Hidehiro Fukuyama
-
Publication number: 20130149793Abstract: The present invention relates to an anti-FDP monoclonal antibody selected from the first, second and third monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent and reagent kit for the measurement of FDP and a method for measurement of FDP using the anti-FDP monoclonal antibodies.Type: ApplicationFiled: January 28, 2013Publication date: June 13, 2013Inventors: Naoya OKITSU, Katsushi KOBAYASHI, Noriaki NAKAJIMA, Masumi MURAKAMI, Kouji SAKAGUCHI, Ayumi ASAEDA, Mayumi SUGIMOTO
-
Publication number: 20130136750Abstract: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.Type: ApplicationFiled: October 23, 2012Publication date: May 30, 2013Applicant: LIFE SCIENCES RESEARCH PARTNERS VZWInventors: Marc G. JACQUEMIN, Jean-Marie R. Saint-Remy
-
Publication number: 20130129745Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: January 31, 2013Publication date: May 23, 2013Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Oregon Health & Science University, Vanderbit University
-
Publication number: 20130129744Abstract: An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.Type: ApplicationFiled: November 2, 2012Publication date: May 23, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventor: National Cheng Kung University
-
Patent number: 8431686Abstract: The present invention relates to a monoclonal antibody binding to the LG4/5 domain of chain alpha3 of human protein laminin-5, wherein said monoclonal antibody inhibits the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, in particular 1H12 monoclonal antibody produced by the hybridoma cell line named 1H12 deposited on Jan. 8, 2008 at the C. N. C. M. under number 1-3890, as well as chimerized, humanized derivatives and fragments thereof, and nucleic acid sequences encoding them, as well as vectors and host cells expressing them. The invention further relates to the medical application of such antibodies, in particular for treating cancer.Type: GrantFiled: December 18, 2009Date of Patent: April 30, 2013Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon IInventors: Patricia Rousselle, Francois Letourneur
-
Patent number: 8420084Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.Type: GrantFiled: March 5, 2010Date of Patent: April 16, 2013Assignees: Medarex, Inc., Oxford BioTherapeutics LtdInventors: Jonathan Alexander Terrett, Heidi Leblanc, Haichun Huang, Erika Meaddough, Chin Pan, Bingliang Chen, Chetana Rao-Naik
-
Publication number: 20130078245Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.Type: ApplicationFiled: August 17, 2012Publication date: March 28, 2013Applicant: The Regents of the University of Colorado, a body CorporateInventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik
-
Patent number: 8404236Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: GrantFiled: February 13, 2012Date of Patent: March 26, 2013Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Patent number: 8404815Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: February 22, 2011Date of Patent: March 26, 2013Assignee: Onclave TherapeuticsInventors: Dale B. Schenk, Peter A. Seubert
-
Patent number: 8394378Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: GrantFiled: September 26, 2011Date of Patent: March 12, 2013Assignee: Janssen Biotech, Inc.Inventors: John Kehoe, Jennifer Lee Gardiner, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler
-
Patent number: 8372398Abstract: The present invention relates to improved Nanobodiesâ„¢ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: GrantFiled: June 24, 2010Date of Patent: February 12, 2013Assignee: Ablynx N.V.Inventor: Karen Silence
-
Patent number: 8372404Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: May 29, 2012Date of Patent: February 12, 2013Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8372403Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: May 1, 2012Date of Patent: February 12, 2013Assignee: Genentech, Inc.Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
-
Patent number: 8367356Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.Type: GrantFiled: August 15, 2007Date of Patent: February 5, 2013Assignee: Beijing Cotimes Biotech Co., Ltd.Inventors: Enyun Shen, Zheng Yu, Min Zhou, Fei Guo
-
Patent number: 8362208Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.Type: GrantFiled: December 14, 2006Date of Patent: January 29, 2013Assignee: Glaxo Group LimitedInventors: Stephanie Jane Clegg, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabinder Kumar Prinjha
-
Patent number: 8357783Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.Type: GrantFiled: March 25, 2009Date of Patent: January 22, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Yang Feng, Ira H. Pastan
-
Patent number: 8343493Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.Type: GrantFiled: October 24, 2008Date of Patent: January 1, 2013Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), SanofiInventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
-
Patent number: 8338379Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.Type: GrantFiled: September 23, 2010Date of Patent: December 25, 2012Assignee: Intellect Neurosciences, Inc.Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
-
Patent number: 8323905Abstract: The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury.Type: GrantFiled: March 20, 2007Date of Patent: December 4, 2012Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Yoshitaka Hosaka, Katsuki Naitoh, Motoyasu Honda
-
Patent number: 8298779Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: August 9, 2011Date of Patent: October 30, 2012Assignee: President and Fellows of Harvard CollegeInventor: Jose A. Halperin
-
Patent number: 8293234Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: March 29, 2010Date of Patent: October 23, 2012Assignee: Life Sciences Research PartnersInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 8283131Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.Type: GrantFiled: October 28, 2008Date of Patent: October 9, 2012Assignee: Assistance Publique-Hopitaux de ParisInventors: Didier Payen De La Garanderie, Anne-Claire Lukaszewicz
-
Patent number: 8282923Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: March 29, 2010Date of Patent: October 9, 2012Assignee: Life Sciences Research PartnersInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20120251549Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: ApplicationFiled: June 15, 2012Publication date: October 4, 2012Applicant: Genentech, Inc.Inventors: MICHAEL S.C. FUNG, Cecily R.Y. Sun, William N.C. Sun
-
Patent number: 8268973Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: July 20, 2011Date of Patent: September 18, 2012Assignee: Onclave TherapeuticsInventors: Dale B. Schenk, Peter A. Seubert, José Saldanha
-
Patent number: 8252284Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: March 27, 2009Date of Patent: August 28, 2012Assignee: Tanox, Inc.Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
-
Patent number: 8252907Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: GrantFiled: March 7, 2011Date of Patent: August 28, 2012Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Robert Lawton
-
Patent number: 8252287Abstract: For the first time, the present invention provides antibodies that enhance the generation of activated blood coagulation factor VIII. The antibodies enhance the cleavage of blood coagulation factor VIII at the Arg of position 372 and suppress the cleavage at the Arg of position 336 by recognizing and binding to the A2 domain of blood coagulation Factor VIII. Such antibodies are expected to be useful in preventing or treating diseases that develop or progress due to decrease or loss of the blood coagulation factor VIII activity, for example, hemophilia A, acquired hemophilia, and von Willebrand's disease.Type: GrantFiled: March 2, 2009Date of Patent: August 28, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, Nara Medical UniversityInventors: Masahiro Takeyama, Keiji Nogami, Midori Shima, Tsukasa Suzuki
-
Publication number: 20120204275Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.Type: ApplicationFiled: February 7, 2012Publication date: August 9, 2012Applicant: Neotope Biosciences LimitedInventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
-
Patent number: 8236315Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.Type: GrantFiled: January 23, 2009Date of Patent: August 7, 2012Assignee: Glenmark Pharmaceuticals, S.A.Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger